Please assess the completion status of the following clinical trial:

Trial Title: Continuing Evaluation of the LungPoint ATV System

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Surgical candidates age 21-75 years at screening~2. Highly suspicious SPN, defined as distinct nodule with a diameter of 10-30 mm in its largest dimension~3. No known endobronchial tumor~4. Tumor located anywhere in parenchymal tissue \>1 cm from pleura and accessible bronchoscopically through a POE.~5. Willing to participate in all aspects of study protocol for duration of study~6. Able to understand study requirements~7. Signs study-related informed consent document~Exclusion Criteria:~1. Any contraindication to bronchoscopy, for example: (a.) Untreatable life-threatening arrhythmias, (b.) Inability to adequately oxygenate the patient during the procedure, (c.) Acute respiratory failure with hypercapnia (unless the patient is intubated and ventilated), (d.) Recent myocardial infarction, (e.) Previously diagnosed high-grade tracheal obstruction, (f.) Uncorrectable coagulopathy.~2. Known coagulopathy~3. Platelet dysfunction or platelet count \< 100 x 103 cells/mm3~4. History of major bleeding with bronchoscopy~5. Pulmonary hypertension with mean PAP \>25 mm~6. Moderate-to-severe pulmonary fibrosis~7. Moderate to severe emphysema or COPD with FEV1 \<60% predicted or RV \>200% predicted~8. Bullae \>5 cm located in vicinity of target SPN or ATV tunnel~9. Any other severe or life-threatening comorbidity that could increase the risk of bronchoscopic biopsy or ATV tunneling, for example: (a.) ASA class \> 3, (b.) \> stage 3 heart failure, (c.) severe cachexia, (d.) severe respiratory insufficiency or hypoxia~10. Ongoing systemic infection~11. Contraindication to general anesthesia~12. Chronic use of anticoagulants (e.g., heparin, Warfarin) or antiplatelet agents (e.g. aspirin, clopidogrel)~13. Participation in any other study in last 30 days~14. Prior thoracic surgery on the same side of the lung as the SPN~15. Breastfeeding women or females of childbearing potential with a positive pregnancy test prior to the procedure or the intent to become pregnant during the study.~16. Life expectancy of less than one year.~17. Patients with known intrapulmonary metastases of extrapulmonary cancer/tumors~18. Scheduled for lung surgery within 7 days post-scheduled diagnostic bronchoscopy

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Navigation and tissue sampling (Type: EXPERIMENTAL): Guided bronchoscopic navigation and lung tissue sampling using the LungPoint ATV System

Based on this trial design, predict the completion outcome and termination type (if applicable).